We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?
Read MoreHide Full Article
Key Takeaways
DexCom raised 2026 revenue guidance and lifted its adjusted gross, operating and EBITDA margin outlooks.
G7 15 Day helped lift Q2 adjusted gross margin to 64.1%, up 400 basis points year over year.
DexCom faces FX pressure, Ireland manufacturing investment and G6 transition costs in the second half.
DexCom, Inc. (DXCM - Free Report) raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves.
The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels.
DexCom’s Q2 Results Reset the 2026 Baseline
DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% year over year, while adjusted earnings reached 70 cents per share. Adjusted operating income increased 48% to $328.3 million, with the adjusted operating margin expanding to 25.1%.
The operating backdrop was broad. U.S. revenues rose 11% to $933.4 million, while international revenues increased 19% to $375 million. International organic growth was 16%, supported by reimbursement expansion and adoption in markets including France and Canada.
DXCM’s Raised Margin Outlook Shows Better Leverage
Management now expects 2026 revenues of $5.18-$5.25 billion, up from the prior $5.16-$5.25 billion range. The updated outlook implies 11-13% annual growth and incorporates stronger organic growth expectations.
Profitability guidance moved higher as well. DexCom raised its adjusted gross margin forecast to about 64%, adjusted operating margin guidance to 23.5%-24% and adjusted EBITDA margin guidance to 31.5%-32%. Those revisions make operating leverage a larger part of the 2026 thesis rather than leaving the story dependent mainly on revenue growth.
DexCom’s G7 15 Day Rollout Supports Profitability
The G7 15 Day transition is helping the margin profile through product mix and manufacturing efficiency. Second-quarter adjusted gross margin reached 64.1%, up 400 basis points year over year, as manufacturing efficiencies and the initial customer switchover to G7 15 Day supported results.
The rollout also broadens the product opportunity. DexCom expects to convert nearly half of its U.S. customer base to G7 15 Day by year-end 2026. Health Canada has cleared the system, while Dexcom Flex has launched in Germany, giving the company additional paths to extend 15-day sensor economics internationally.
DXCM’s FX and Execution Risks Could Offset Progress
The higher outlook still carries offsets. DexCom expects a roughly $15 million foreign-exchange headwind to second-half 2026 international revenues. The company is also investing in its Ireland manufacturing facility, while the transition away from G6 brings inventory and execution costs that can complicate near-term efficiency gains.
Competition can further influence pricing, rebates and channel mix. Abbott Laboratories (ABT - Free Report) continues to expand its FreeStyle Libre continuous glucose monitoring franchise, including use in type 2 diabetes. Senseonics Holdings, Inc. (SENS - Free Report) markets the implantable Eversense 365 system, giving patients and payers another differentiated continuous glucose monitoring option.
DexCom’s Signal Check Keeps Expectations Grounded
The margin upgrades improve DXCM’s fundamental setup, and earnings estimates have moved higher. Over the past 60 days, estimates for 2026 and 2027 rose 2.7% and 1.2% to $2.65 and $3.08 per share, respectively. The stock, however, trades at 30.7X forward 12-month earnings, above 27.3X for the Zacks sub-industry, 21.2X for the Medical sector and 20.7X for the S&P 500.
Raised guidance and improving estimates support the margin story, but the valuation premium, foreign-exchange pressure and execution demands keep the case balanced rather than decisively bullish.
View the Zacks #1 Rank List
Image: Bigstock
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?
Key Takeaways
DexCom, Inc. (DXCM - Free Report) raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves.
The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels.
DexCom’s Q2 Results Reset the 2026 Baseline
DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% year over year, while adjusted earnings reached 70 cents per share. Adjusted operating income increased 48% to $328.3 million, with the adjusted operating margin expanding to 25.1%.
DexCom, Inc. Revenue (Quarterly)
DexCom, Inc. revenue-quarterly | DexCom, Inc. Quote
The operating backdrop was broad. U.S. revenues rose 11% to $933.4 million, while international revenues increased 19% to $375 million. International organic growth was 16%, supported by reimbursement expansion and adoption in markets including France and Canada.
DXCM’s Raised Margin Outlook Shows Better Leverage
Management now expects 2026 revenues of $5.18-$5.25 billion, up from the prior $5.16-$5.25 billion range. The updated outlook implies 11-13% annual growth and incorporates stronger organic growth expectations.
Profitability guidance moved higher as well. DexCom raised its adjusted gross margin forecast to about 64%, adjusted operating margin guidance to 23.5%-24% and adjusted EBITDA margin guidance to 31.5%-32%. Those revisions make operating leverage a larger part of the 2026 thesis rather than leaving the story dependent mainly on revenue growth.
DexCom’s G7 15 Day Rollout Supports Profitability
The G7 15 Day transition is helping the margin profile through product mix and manufacturing efficiency. Second-quarter adjusted gross margin reached 64.1%, up 400 basis points year over year, as manufacturing efficiencies and the initial customer switchover to G7 15 Day supported results.
The rollout also broadens the product opportunity. DexCom expects to convert nearly half of its U.S. customer base to G7 15 Day by year-end 2026. Health Canada has cleared the system, while Dexcom Flex has launched in Germany, giving the company additional paths to extend 15-day sensor economics internationally.
DXCM’s FX and Execution Risks Could Offset Progress
The higher outlook still carries offsets. DexCom expects a roughly $15 million foreign-exchange headwind to second-half 2026 international revenues. The company is also investing in its Ireland manufacturing facility, while the transition away from G6 brings inventory and execution costs that can complicate near-term efficiency gains.
Competition can further influence pricing, rebates and channel mix. Abbott Laboratories (ABT - Free Report) continues to expand its FreeStyle Libre continuous glucose monitoring franchise, including use in type 2 diabetes. Senseonics Holdings, Inc. (SENS - Free Report) markets the implantable Eversense 365 system, giving patients and payers another differentiated continuous glucose monitoring option.
DexCom’s Signal Check Keeps Expectations Grounded
The margin upgrades improve DXCM’s fundamental setup, and earnings estimates have moved higher. Over the past 60 days, estimates for 2026 and 2027 rose 2.7% and 1.2% to $2.65 and $3.08 per share, respectively. The stock, however, trades at 30.7X forward 12-month earnings, above 27.3X for the Zacks sub-industry, 21.2X for the Medical sector and 20.7X for the S&P 500.
Image Source: Zacks Investment Research
DXCM currently carries a Zacks Rank #3 (Hold). Likewise, Abbott and Senseonics carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Raised guidance and improving estimates support the margin story, but the valuation premium, foreign-exchange pressure and execution demands keep the case balanced rather than decisively bullish.